36,010 results match your criteria Lymphoma Lymphoblastic


Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: A retrospective study from China.

Asia Pac J Clin Oncol 2021 Jun 23. Epub 2021 Jun 23.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Aim: Little is known about the outcome and prognostic factors of relapsed or refractory T-cell lymphoblastic lymphoma (T-LBL), especially in adult patients. The aim of this study was to analyze the characteristics, outcome and prognostic factors for this patient population.

Methods: Between January 2006 and December 2017, we retrospectively analyzed 84 adult patients with T-LBL, and 44 relapsed or primary refractory patients were included in this analysis. Read More

View Article and Full-Text PDF

Multifocal precursor B-cell lymphoblastic lymphoma in an infant with cardiac involvement: A case report.

Radiol Case Rep 2021 Aug 8;16(8):2054. Epub 2021 Jun 8.

Department of Radiology, Ha Noi Medical University, Ha Noi, Vietnam.

Lymphoma with cardiac involvement is a high-risk lesion, especially in children. We report a rare clinical case of multifocal precursor B-cell lymphoblastic lymphoma in a child with cardiac involvement. A 4-year-old boy presented to the Vietnam National Children's Hospital with a vague headache, but magnetic resonance imaging of the head was normal. Read More

View Article and Full-Text PDF

T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association.

Ecancermedicalscience 2021 22;15:1221. Epub 2021 Apr 22.

Department of Histopathology, The Children's Hospital & Institute of Child Health, Ferozepur Road, Lahore 54400, Pakistan.

Lymphoblastic lymphoma and chronic myeloid leukaemia (CML) are two distinct neoplasms with different pathogenesis and clinical presentation. We hereby share a challenging case of a child presenting with fever, leucocytosis, generalised lymphadenopathy and massive splenomegaly. He was diagnosed as having novel association of concurrent T-lymphoblastic lymphoma diagnosed on cervical lymph node biopsy with BCR-ABL negative CML on bone marrow aspirate. Read More

View Article and Full-Text PDF

Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.

Cancer Gene Ther 2021 Jun 22. Epub 2021 Jun 22.

Human Genetics Research Center, Tehran, Iran., Baqiyatallah University of Medical Sciences, Tehran, Iran.

Chimeric antigen receptor (CAR) T-cell therapy is an encouraging and fast-growing platform used for the treatment of various types of tumors in human body. Despite the recent success of CAR T-cell therapy in hematologic malignancies, especially in B-cell lymphoma and acute lymphoblastic leukemia, the application of this treatment approach in solid tumors faced several obstacles resulted from the heterogeneous expression of antigens as well as the induction of immunosuppressive tumor microenvironment. Oncolytic virotherapy (OV) is a new cancer treatment modality by the use of competent or genetically engineered viruses to replicate in tumor cells selectively. Read More

View Article and Full-Text PDF

Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.

J Clin Oncol 2021 Jun 22:JCO2003458. Epub 2021 Jun 22.

Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.

Purpose: CD19-targeted chimeric antigen receptor (CAR)-modified T cells demonstrate unprecedented responses in B-cell acute lymphoblastic leukemia (B-ALL); however, relapse remains a substantial challenge. Short CAR T-cell persistence contributes to this risk; therefore, strategies to improve persistence are needed.

Methods: We conducted a pilot clinical trial of a humanized CD19 CAR T-cell product (huCART19) in children and young adults with relapsed or refractory B-ALL (n = 72) or B-lymphoblastic lymphoma (n = 2), treated in two cohorts: with (retreatment, n = 33) or without (CAR-naive, n = 41) prior CAR exposure. Read More

View Article and Full-Text PDF

[CAR T-cell therapy for malignant B-cell lymphoma : A new treatment paradigm].

Internist (Berl) 2021 Jun 21;62(6):589-596. Epub 2021 Jun 21.

Uniklinik Köln, Medizinische Klinik 1, 50937, Köln, Deutschland.

Following the first demonstration of efficacy of anti-CD19-directed chimeric antigen receptor (CAR) T cells in a patient with relapsed chronic lymphocytic leukemia (CLL) in 2011, pivotal studies for this innovative therapy were initially conducted in multiple relapsed or refractory (r/r) childhood and young adult acute B‑cell leukemia and in aggressive adult B‑cell lymphoma. The studies demonstrated efficacy even in chemotherapy-refractory disease, resulting in the first approval of autologous and genetically engineered T cells for the treatment of r/r B‑cell acute lymphoblastic leukemia (B-ALL) in the US for the product tisagenlecleucel (Kymriah®, Novartis) back in 2018. Approval for the treatment of r/r aggressive B‑cell lymphoma followed shortly thereafter for tisagenlecleucel and axicabtagene ciloleucel (Yescarta, Kite/Gilead). Read More

View Article and Full-Text PDF

Racial and ethnic disparities in pediatric cancer incidence among children and young adults in the United States by single year of age.

Cancer 2021 Jun 21. Epub 2021 Jun 21.

Division of Pediatric Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.

Background: Incidence rates of pediatric cancers in the United States are typically reported in 5-year age groups, obscuring variation by single year of age. Additionally, racial and ethnic variation in incidence is typically presented in broad categories rather than by narrow age ranges.

Methods: The Surveillance, Epidemiology, and End Results (SEER) 18 data (2000-2017) were examined to calculate frequencies and age-adjusted incidence rates among individuals aged birth to 39 years. Read More

View Article and Full-Text PDF

Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor.

Front Med (Lausanne) 2021 4;8:604085. Epub 2021 Jun 4.

Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.

Graft failure (GF) is a fatal complication of allogeneic stem cell transplantation, especially after haploidentical transplantation. The mortality of GF is nearly 100% without an effective salvage method. A second transplantation is usually necessary to save the patient's life. Read More

View Article and Full-Text PDF

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies.

Cell Transplant 2021 Jan-Dec;30:9636897211025503

Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Chimeric antigen receptor T cells (CAR-Ts) constitute a novel therapeutic strategy for relapsed/refractory B-cell malignancies. With the extensive application of CAR-T therapy in clinical settings, CAR-T-associated toxicities have become increasingly apparent. However, information regarding the associated infections is limited. Read More

View Article and Full-Text PDF

Loncastuximab Tesirine: First Approval.

Authors:
Arnold Lee

Drugs 2021 Jun 18. Epub 2021 Jun 18.

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Loncastuximab tesirine (loncastuximab tesirine-lpyl; ZYNLONTA™) is an antibody-drug conjugate being developed for the treatment of B cell lymphomas by ADC Therapeutics SA. Loncastuximab tesirine consists of a pyrrolobenzodiazepine DNA-alkylating warhead covalently attached via a cleavable linker to an anti-CD19 antibody that binds to B cells. It is currently approved in the US for the treatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL), and is being developed for the treatment of mantle-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia. Read More

View Article and Full-Text PDF

Point-of-Care Ultrasound Assists in Rapid Diagnosis of T-cell Lymphoblastic Lymphoma in a Young Boy.

Cureus 2021 May 12;13(5):e14978. Epub 2021 May 12.

Department of Emergency and Hospital Medicine, University of South Florida Morsani College of Medicine/Lehigh Valley Health Network Campus, Allentown, USA.

T-cell lymphoblastic lymphoma (T-cell LBL) is an uncommon diagnosis for acute dyspnea in pediatric emergencies. This case details a 13-year-old boy presenting to the ED with dyspnea, who was diagnosed with T-cell LBL. It was a unique presentation in which there was no obvious mediastinal mass on the examination or primary imaging. Read More

View Article and Full-Text PDF

The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay.

Fam Cancer 2021 Jun 15. Epub 2021 Jun 15.

Department of Pediatric Hematology-Oncology, "Aghia Sophia" Children's Hospital, Thivon 1 & Papadiamantopoulou, 11527, Athens, Greece.

Hematological malignancies (HM) developed on underlying primary immunodeficiencies (PID) are rare and of unusual features. Differentiating between malignant and non-malignant lymphoproliferation in cases of pediatric hematology and oncology and revealing their molecular predisposition demonstrate the complex interplay between PID and HM. We retrospectively studied a case series of seven pediatric patients, all with PID with manifestations raising suspicion for HM or hypereosinophilic syndrome (HES) or confirmed HM of lymphoid origin. Read More

View Article and Full-Text PDF

Family history of early onset acute lymphoblastic leukemia is suggesting genetic associations.

Sci Rep 2021 Jun 11;11(1):12370. Epub 2021 Jun 11.

Center for Primary Health Care Research, Lund University, Malmö, Sweden.

Childhood acute lymphoblastic leukemia (ALL) has an origin in the fetal period which may distinguish it from ALL diagnosed later in life. We wanted to test whether familial risks differ in ALL diagnosed in the very early childhood from ALL diagnosed later. The Swedish nation-wide family-cancer data were used until year 2016 to calculate standardized incidence ratios (SIRs) for familial risks in ALL in three diagnostic age-groups: 0-4, 5-34 and 35 + years. Read More

View Article and Full-Text PDF

Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review.

Medicine (Baltimore) 2021 Jun;100(23):e26323

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Rationale: B-lymphoblastic lymphoma (B-LBL) with BCR/ABL mutation (Ph+ B-LBL) is a rare type of cancer in both childhood and adults. Its clinical manifestations are similar to those of other types lymphoma. However, the targeted therapy can substantially improve the outcome of Ph+ B-LBL. Read More

View Article and Full-Text PDF

Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.

Blood 2021 Jun 10. Epub 2021 Jun 10.

St Jude Children's Research Hospital, Memphis, Tennessee, United States.

CRLF2-rearranged (CRLF2r) acute lymphoblastic leukemia (ALL) comprises over half of Philadelphia chromosome-like (Ph-like) ALL, is associated with poor outcome in children and adults. Overexpression of CRLF2 results in activation of JAK-STAT and parallel signaling pathways in experimental models, but existing small molecule inhibitors of Janus kinases show variable and limited efficacy. Here we evaluated the efficacy of proteolysis-targeting chimeras (PROTACs) directed against Janus kinases. Read More

View Article and Full-Text PDF

Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.

Medicine (Baltimore) 2021 May;100(19):e25786

Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Rationale: Significant concerns about the adverse effects following chimeric antigen receptor T cell (CAR-T) therapy are still remained including cytokine release syndrome (CRS). In rare circumstances, CRS may be refractory to tocilizumab and/or corticosteroids, a new treatment is needed for the management of CRS.

Patient Concerns: We present a case of a 20-year-old male patient with acute lymphoblastic leukemia developed CRS after CD19/CD22 bispecific CAR-T treatment. Read More

View Article and Full-Text PDF

[Analysis on Death Cases in Children with Acute Lymphoblastic Leukemia Treated with the CCLG-ALL 2008 Protocol].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):720-724

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China,E-mail:

Objective: To retrospective analyze the reason of death in children with acute lymphoblastic leukemia (ALL) treated with CCLG-ALL 2008 protocol, and the experience was summarized in order to reduce the mortality.

Methods: 916 children diagnosed as ALL and accepted CCLG-ALL 2008 protocol from April 2008 to April 2015 in our hospital were enrolled, the dead cases in them were analyzed retrospectively.

Results: 169 children died, including 111 (65. Read More

View Article and Full-Text PDF

[Relationship between IKZF3 Gene Single Nucleotide Polymorphisms and Childhood Acute Lymphoblastic Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):690-695

Department of Hematology,Guangzhou Women and Children's Medical Center, Guangzhou 510623, Guangdong Province, China,E-mail:

Objective: To investigate the relationship between single nucleotide polymorphisms (SNPs) of IKAROS family Zinc finger 3 (IKZF3) gene and the risk of acute lymphoblastic leukemia (ALL) in children.

Methods: The peripheral blood samples from 286 children with ALL and 382 healthy children were collected and divided into ALL group and control group, respectively. The genotypes of IKZF3 gene at rs62066988 C > T and rs12946510 C > T were detected by quantitative PCR with TaqMan detection system, and their correlation with ALL was analyzed. Read More

View Article and Full-Text PDF

[The Factors Related to Treatment Failure in Children with Acute Lymphoblastic Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):661-668

Department of Hematology, Children's Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China,E-mail:

Objective: To analyze the efficacy of CCLG-ALL-2008 protocol and the related factors of treatment failure in children with acute lymphoblastic leukemia (ALL).

Methods: The clinical data of 400 children newly-diagnosed ALL in Children's Hospital of Soochow University from March 1, 2008 to December 31, 2012 was retrospectively analyzed. All the children accepted CCLG-ALL-2008 protocol, and were followed-up until October 2019. Read More

View Article and Full-Text PDF

[Management of pediatric leukemia].

Soins Pediatr Pueric 2021 May-Jun;42(320):35-40. Epub 2021 Mar 26.

Faculté de médecine, Sorbonne Université, 91105 boulevard de l'Hôpital, 75013 Paris, France; Service d'hématologie et d'oncologie pédiatrique, Hôpital Armand-Trousseau, AP-HP, 26 avenue du Docteur-Arnold-Netter, 75012 Paris, France.

Acute leukemias are the most common pediatric cancer. With a cure rate of about 80%, their treatment is based on a combination of cytotoxic chemotherapies whose intensity is adapted to prognostic factors. Sometimes, allogeneic hematopoietic stem cell transplantation is indicated. Read More

View Article and Full-Text PDF

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.

Lancet 2021 Jun 3. Epub 2021 Jun 3.

Kite, a Gilead Company, Santa Monica, CA, USA.

Background: Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, underlining the need for more effective therapies.

Methods: We report the pivotal phase 2 results of ZUMA-3, an international, multicentre, single-arm, open-label study evaluating the efficacy and safety of the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Patients were enrolled at 25 sites in the USA, Canada, and Europe. Read More

View Article and Full-Text PDF

Oral and oropharyngeal lymphomas: a multi-institutional collaborative study.

J Oral Pathol Med 2021 Jun 6. Epub 2021 Jun 6.

Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Background: Lymphomas in the oral and oropharyngeal regions are relatively uncommon and their diagnosis is challenging and complex due to the myriad histopathological subtypes. Herein, we report a large series of oral and oropharyngeal lymphomas and compare our data with the currently available literature.

Methods: All cases diagnosed as lymphomas affecting the oral and oropharyngeal regions were retrospectively retrieved from seven Brazilian institutions. Read More

View Article and Full-Text PDF

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments.

Curr Hematol Malig Rep 2021 Jun 5. Epub 2021 Jun 5.

Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 2201 Inwood Road, Dallas, TX, 76034, USA.

Purpose Of Review: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive.

Recent Findings: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. Read More

View Article and Full-Text PDF

Impact of the COVID-19 pandemic on paediatric patients with cancer in low-income, middle-income and high-income countries: protocol for a multicentre, international, observational cohort study.

BMJ Open 2021 06 2;11(6):e045679. Epub 2021 Jun 2.

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

Introduction: Childhood cancers are a leading cause of non-communicable disease deaths for children around the world. The COVID-19 pandemic may have impacted on global children's cancer services, which can have consequences for childhood cancer outcomes. The Global Health Research Group on Children's Non-Communicable Diseases is currently undertaking the first international cohort study to determine the variation in paediatric cancer management during the COVID-19 pandemic, and the short-term to medium-term impacts on childhood cancer outcomes. Read More

View Article and Full-Text PDF

Gene Expression and Survival of Acute Lymphoblastic Leukemia Cells After Allogeneic Transplant.

Anticancer Res 2021 Jun;41(6):2781-2793

Division of Pediatric Hematology/Oncology, University of Rochester, Rochester, NY, U.S.A.

Background/aim: This study explored the mechanisms of the allogeneic graft versus leukemia effect in acute lymphoblastic leukemia (ALL) cells by examining whether they change gene expression in the post-transplant environment containing cytokines and the immunosuppressant cyclosporine, and if such changes affect ALL cell survival.

Materials And Methods: RNASeq was used to assess leukemia global gene expression and flow cytometry to measure ALL survival in the presence of T cells, NK cells, cytokines, and cyclosporine.

Results: A total of 4,805 genes were differentially expressed. Read More

View Article and Full-Text PDF

LYNX (LYmphoid NeXt-generation sequencing) panel: a comprehensive capture-based sequencing tool for the analysis of prognostic and predictive markers in lymphoid malignancies.

J Mol Diagn 2021 May 31. Epub 2021 May 31.

Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital Brno, Czech Republic; Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Czech Republic. Electronic address:

B-cell neoplasms represent a clinically heterogeneous group of hematological malignancies with considerably diverse genomic architecture recently endorsed by next-generation sequencing (NGS) studies. Since multiple genetic defects have potential or confirmed clinical impact, a tendency toward more comprehensive testing of diagnostic, prognostic, and predictive markers is desired. In this study, we introduce the design, validation, and implementation of an integrative custom-designed capture-based NGS panel titled LYNX (LYmphoid NeXt-generation sequencing) for the analysis of standard and novel molecular markers in the most common lymphoid malignancies (chronic lymphocytic leukemia, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma). Read More

View Article and Full-Text PDF

Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes.

Leuk Lymphoma 2021 Jun 3:1-14. Epub 2021 Jun 3.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

The treatment landscape for patients with acute lymphoblastic leukemia (ALL) is changing. Continued investigation into the biology of ALL, and broader use and more precise methods of measuring residual disease allow for improved risk stratification of patients and identification of the subset of patients at greatest risk of disease relapse and who may benefit from hematopoietic cell transplantation (HCT) in first complete remission. Further, recent advances in HCT preparative regimens, donor selection, graft manipulation, and graft-versus-host disease prophylaxis and treatment have resulted in fewer transplant-related morbidities and mortality and better survival outcomes. Read More

View Article and Full-Text PDF

The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia.

Cancer Med 2021 Jun 2. Epub 2021 Jun 2.

Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.

Background: Treatment on risk adapted intensive pediatric protocols has improved outcome for teenagers and young adults (TYA) with T-cell acute lymphoblastic leukemia (T-ALL). Understanding the biology of disease in this age group and the genetic basis of relapse is a key goal as patients with relapsed/refractory disease have poor outcomes with conventional chemotherapy and novel molecular targets are required. This study examines the question of whether TYA T-ALL has a specific biological-molecular profile distinct from pediatric or adult T-ALL. Read More

View Article and Full-Text PDF

Mediastinal Lymphoproliferative Disorders.

Adv Anat Pathol 2021 Jun 2. Epub 2021 Jun 2.

Department of Pathology and Laboratory Services, University of Arkansas for Medical Sciences, Little Rock, AR.

Lymphoproliferative disorders comprise 50% to 60% of all mediastinal malignancies in both children and adults. Primary mediastinal involvement is rare (∼5%), whereas secondary mediastinal involvement by systemic disease is more common (10% to 25%). Primary mediastinal disease is defined as involvement by a lymphoproliferative disorder of mediastinal lymph nodes, the thymus, and/or extranodal mediastinal organs without evidence of systemic disease at presentation. Read More

View Article and Full-Text PDF

MicroRNA as a Prognostic and Diagnostic Marker in T-Cell Acute Lymphoblastic Leukemia.

Int J Mol Sci 2021 May 18;22(10). Epub 2021 May 18.

Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.

T cell acute lymphoblastic leukemia (T-ALL) is a biologically and genetically heterogeneous disease with a poor prognosis overall and several subtypes. The neoplastic transformation takes place through the accumulation of numerous genetic and epigenetic abnormalities. There are only a few prognostic factors in comparison to B cell precursor acute lymphoblastic leukemia, which is characterized by a lower variability and more homogeneous course. Read More

View Article and Full-Text PDF